Ensuring global access to COVID-19 vaccines

CEPI estimates that developing up to three vaccines in the next 12–18 months will require an investment of at least US$2 billion.4 This estimate includes phase 1 clinical trials of eight vaccine candidates, progression of up to six candidates through phase 2 and 3 trials, completion of regulatory an...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet 2020-05, Vol.395 (10234), p.1405-1406
Main Authors: Yamey, Gavin, Schäferhoff, Marco, Hatchett, Richard, Pate, Muhammad, Zhao, Feng, McDade, Kaci Kennedy
Format: Article
Language:English
Subjects:
Betacoronavirus
Clinical trials
Comment
Coronavirus Infections - epidemiology
Coronavirus Infections - prevention & control
Coronaviruses
COVID-19
COVID-19 Vaccines
Disease transmission
Drug delivery systems
Drug Development - economics
Drug Industry
Epidemics
Finance
Financing
Funding
Funds
Global Health
Health Services Accessibility
Health Services Needs and Demand
Humans
Immunization
Innovations
International finance
International financing
Malaria
Pandemics
Pandemics - prevention & control
Pneumonia, Viral - epidemiology
Pneumonia, Viral - prevention & control
Resource Allocation
SARS-CoV-2
Tuberculosis
Vaccines
Vector-borne diseases
Viral Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:CEPI estimates that developing up to three vaccines in the next 12–18 months will require an investment of at least US$2 billion.4 This estimate includes phase 1 clinical trials of eight vaccine candidates, progression of up to six candidates through phase 2 and 3 trials, completion of regulatory and quality requirements for at least three vaccines, and enhancing global manufacturing capacity for three vaccines. In addition to direct government contributions, innovative finance mechanisms have been successful in raising funds for vaccines in the past and should be used to fund the development of COVID-19 vaccines.8,9 The International Finance Facility for Immunisation (IFFIm) raises funds with vaccine bonds, which turn long-term contributions by donors into available cash.8 IFFIm was created to support Gavi, the Vaccine Alliance, but could be used to finance CEPI's COVID-19 vaccine efforts. Investments should proceed in tandem to build national systems for delivery of potential vaccines—eg, using domestic financing and external financing from the World Bank Group's $14 billion COVID-19 Fast Track Facility13 and reallocations from the Global Fund to Fight AIDS, Tuberculosis and Malaria, Gavi, and Global Financing Facility grants for service delivery.
ISSN:0140-6736
1474-547X
1474-547X
DOI:10.1016/S0140-6736(20)30763-7